Jeffrey S. Heier Sells 2,948 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey S. Heier sold 2,948 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the sale, the insider now directly owns 269,059 shares in the company, valued at approximately $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ocular Therapeutix Stock Up 3.2 %

OCUL opened at $10.06 on Thursday. The firm has a market capitalization of $1.58 billion, a P/E ratio of -7.62 and a beta of 1.26. Ocular Therapeutix, Inc. has a one year low of $2.16 and a one year high of $11.77. The company has a fifty day moving average price of $9.94 and a 200-day moving average price of $8.21. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Analysts Set New Price Targets

A number of research firms recently weighed in on OCUL. Robert W. Baird reduced their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Scotiabank began coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target for the company. Finally, HC Wainwright boosted their price objective on Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, November 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Institutional Investors Weigh In On Ocular Therapeutix

Large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC increased its stake in Ocular Therapeutix by 12.7% in the 2nd quarter. Avoro Capital Advisors LLC now owns 8,060,000 shares of the biopharmaceutical company’s stock worth $55,130,000 after acquiring an additional 911,064 shares during the last quarter. Vanguard Group Inc. raised its stake in Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 2,117,029 shares in the last quarter. Opaleye Management Inc. lifted its position in Ocular Therapeutix by 9.6% during the first quarter. Opaleye Management Inc. now owns 6,653,138 shares of the biopharmaceutical company’s stock valued at $60,544,000 after purchasing an additional 583,138 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix during the third quarter valued at approximately $24,584,000. Finally, Point72 Asset Management L.P. purchased a new position in Ocular Therapeutix in the 2nd quarter worth approximately $18,514,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.